Skip to content
2000
Volume 23, Issue 7
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Alzheimer’s disease (AD) is a neurodegenerative, progressive, and fatal disorder characterized by marked atrophy of the cerebral cortex and loss of basal forebrain cholinergic neurons. The main pathological features of AD are related to neuronal degeneration and include extracellular deposition of amyloid beta plaques (Aβ plaques), intracellular formation of neurofibrillary tangles (NFTs), and neuroinflammation. So far, drugs used to treat AD have symptomatic and palliative pharmacological effects, disappearing with continued use due to neuron degeneration and death. Therefore, there are still problems with an effective drug for treating AD. Few approaches evaluate the action of natural products other than alkaloids on the molecular targets of β-amyloid protein (Aβ protein) and/or tau protein, which are important targets for developing neuroprotective drugs that will effectively contribute to finding a prophylactic drug for AD. This review gathers and categorizes classes of natural products, excluding alkaloids, which in silico analysis (molecular docking) and in vitro and/or in vivo assays can inhibit the BACE1 and GSK-3β enzymes involved in AD.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557523666221118113923
2023-04-01
2025-10-03
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557523666221118113923
Loading

  • Article Type:
    Review Article
Keyword(s): Alzheimer; BACE1; GSK3β; molecular docking; natural products; non-alkaloids
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test